| 0 (0%) | 03-09 20:25 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.59 | 1-year : | 3.02 |
| Resists | First : | 2.22 | Second : | 2.59 |
| Pivot price | 1.83 |
|||
| Supports | First : | 1.7 | Second : | 1.37 |
| MAs | MA(5) : | 1.81 |
MA(20) : | 1.77 |
| MA(100) : | 1.86  |
MA(250) : | 1.62 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 46.8 |
D(3) : | 41.6 |
| RSI | RSI(14): 59.4 |
|||
| 52-week | High : | 3.53 | Low : | 0.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CRBU ] has closed below upper band by 26.8%. Bollinger Bands are 18.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.83 - 1.84 | 1.84 - 1.85 |
| Low: | 1.65 - 1.66 | 1.66 - 1.67 |
| Close: | 1.8 - 1.82 | 1.82 - 1.84 |
Sat, 07 Mar 2026
Will CRBU stock return to pre crisis levels - 2026 Setups & Growth Oriented Trade Recommendations - Naître et grandir
Sat, 07 Mar 2026
Caribou Biosciences Q3 Losses Reinforce Bearish Narratives On Profitability Risks - Sahm
Fri, 06 Mar 2026
Clear Street Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $13 - 富途牛牛
Thu, 05 Mar 2026
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Thu, 05 Mar 2026
CRBU: Strong clinical progress and improved financials position the pipeline for pivotal trials - TradingView
Thu, 05 Mar 2026
BRIEF-Caribou Biosciences Q4 Licensing And Collaboration Revenue USD 3.941 Million - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 8.44e+007 (%) |
| Held by Institutions | 9.9 (%) |
| Shares Short | 6,790 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3569e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 337.5 % |
| Return on Equity (ttm) | -32.5 % |
| Qtrly Rev. Growth | 9.29e+006 % |
| Gross Profit (p.s.) | 3.37 |
| Sales Per Share | -29.13 |
| EBITDA (p.s.) | -4.67686e+007 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -126 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 3.3 |
| Dividend | 0 |
| Forward Dividend | 7.77e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|